Progress of apatinib in the treatment of ovarian cancer / 中国综合临床
Clinical Medicine of China
; (12): 563-567, 2022.
Article
em Zh
| WPRIM
| ID: wpr-956419
Biblioteca responsável:
WPRO
ABSTRACT
Ovarian cancer (OC) has the highest mortality rate among gynecological malignancies. Its treatment has always been a difficult problem and the focus of exploration in the medical field. In recent years, anti-angiogenic drugs have shown good anticancer effects in the treatment of ovarian cancer. As a new generation of antiangiogenic drugs, apatinib has been proved to have a good therapeutic effect in the treatment of ovarian cancer with less adverse reactions. Therefore, we review the research progress of apatinib in ovarian cancer.
Texto completo:
1
Base de dados:
WPRIM
Idioma:
Zh
Revista:
Clinical Medicine of China
Ano de publicação:
2022
Tipo de documento:
Article